Luna, Paula C.
Chu, Chia-Yu
Fatani, Mohammad
Borlenghi, Cecilia
Adora, Anna
Llamado, Lyndon Q.
Wee, James
Funding for this research was provided by:
Pfizer
Article History
Received: 11 July 2023
Accepted: 18 October 2023
First Online: 23 November 2023
Declarations
:
: Paula C. Luna has served as investigator, speaker, and advisor for AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Pfizer, Sandoz, and Sanofi. Chia-Yu Chu is an investigator for AbbVie, Amgen, Lilly, Novartis, Oneness Biotech, Pfizer, Regeneron, Roche, Sanofi, and United BioPharma; a consultant for AbbVie, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, United BioPharma, and Viatris; a speaker for AbbVie, Lilly, Mylan, Novartis, Pfizer, Roche, Sanofi, and Viatris; and an advisory board member for AbbVie, Janssen, Lilly, Mylan, Novartis, Pfizer, Roche, Sanofi, and Viatris. Mohammad Fatani has received honoraria for speaking and serving as a consultant for AbbVie, Novartis, Eli Lilly, and Newbridge. Cecilia Borlenghi, Anna Adora, Lyndon Q. Llamado, and James Wee are employees and stockholders of Pfizer.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.